Sutro Biopharma, Inc.
STRO
Rank in Stocks
#17235
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the... Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Share Price
$10.61
Last synced: 2026-11-09
Market Cap
$175.93M
Change (1 day)
10.29%
Change (1 year)
30.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sutro Biopharma, Inc. (STRO)
Category
Healthcare
Operating Margin for Sutro Biopharma, Inc. (STRO)
Operating Margin as of November 2026 TTM: -309.87%
According to Sutro Biopharma, Inc.'s latest financial reports, its current operating margin (TTM) is -309.87%. At the end of 2025 the company had an operating margin of -102.41%.
Operating Margin history for Sutro Biopharma, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -309.87% | 202.58% |
| 2025 | -102.41% | -73.35% |
| 2024 | -384.34% | 561.86% |
| 2023 | -58.07% | -69.48% |
| 2022 | -190.26% | 19.50% |
| 2021 | -159.22% | -4.27% |
| 2020 | -166.32% | 28.15% |
| 2019 | -129.79% | 33.96% |
| 2018 | -96.89% | 160.11% |
| 2017 | -37.25% | -1,733.77% |
| 2016 | 2.28% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.12% |
US
|
|
| -149.01% | -99.52% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sutro Biopharma, Inc.'s operating margin
What is Sutro Biopharma, Inc.'s operating margin?
Sutro Biopharma, Inc.'s operating margin is -309.87%, as of Nov 2026.
What was Sutro Biopharma, Inc.'s operating margin in 2025?
In 2025, Sutro Biopharma, Inc.'s operating margin was -102.41%, compared with -384.34% in 2024.
How has Sutro Biopharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Sutro Biopharma, Inc.'s operating margin was highest in 2023 (-58.07%) and lowest in 2024 (-384.34%).
How does Sutro Biopharma, Inc.'s operating margin compare with similar companies?
Sutro Biopharma, Inc.'s operating margin (-309.87%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.